FDA/EMA AI Principles: Role-Based Roadmap for Regulated Pharma Companies

February 23, 2026Dr. Sangeetha Venkataraman

In January 2026, the FDA and EMA jointly published their “Guiding Principles of Good AI Practice in Drug Development– a landmark collaboration building on prior talks like the 2024 FDA-EU bilateral meeting and EMA’s AI reflection paper. This set of 10 high-level principles aims to harmonize expectations for responsible AI use across the full drug lifecycle, from early research to post-market safety, fostering innovation while prioritizing patient protection and reliable evidence.

These principles are not a checklist for approval, but expectations regulators use to assess credibility, reliability, and fitness for purpose of AI/ML used across the drug development lifecycle.

Interpreting them through a role-based lens shows how different functions in a regulated company must collaborate to implement them effectively.

The principles: Implications on Regulated Companies

These 10 principles translate to actionable steps that help companies manage regulatory risk, ensure data integrity, and build strong AI workflows. They emphasize scaling controls proportionally to impact, allowing low-risk applications to progress with streamlined oversight, while higher-risk uses undergo deeper validation and rigorous review.

For regulated firms, this means embedding AI governance into existing GxP systems rather than building in silos. Companies that interpret these principles proactively can use AI to strengthen submissions with better predictions, while avoiding delays from inadequate validation or bias issues.

Role-Based Impact: Who Does What

Each principle affects specific roles in a typical regulated company. Here’s how they map, with practical implications for daily work.

Principle	Key Roles Impacted	What It Means for Them
1. Human-centric by design	Clinicians, Medical Affairs, Pharmacovigilance, End-Users of AI tools	Human experts must retain final decision authority, with AI used as decision support rather than replacement for clinical judgment. They are expected to review and contextualize AI outputs before making patient-impacting or regulatory-relevant decisions. Requires that intended users can understand limitations, failure modes and appropriate reliance on AI outputs.
2. Risk-based approach	Risk Management, Quality Assurance	Classify and manage AI applications based on their specific context of use, applying controls and oversight proportionally to potential impact. Risk should tie directly to factors like patient safety, trial integrity, and influence on regulatory decisions – not the technology alone. This enables efficient processes for lower-risk tools while ensuring rigorous safeguards for high-stakes applications.
3. Adherence to standards	IT/Tech, Data Science	Ensure AI technologies comply with relevant legal, ethical, technical, scientific, cybersecurity, and regulatory standards – including ICH guidelines and GxP – while demonstrating awareness of emerging ML standards. Companies should justify approaches where standards evolve, rather than applying blind compliance, to support audits and seamless interoperability with CROs and vendors.
4. Clear context of use	Regulatory Affairs, Program Leads	Define and document the precise intended context of use for each AI tool in protocols, submissions, and governance docs – including what it is not intended to do. This anchors risk assessment, validation, and performance expectations, preventing off-label applications and facilitating smoother regulatory interactions.
5. Multidisciplinary expertise	Cross-functional (All)	Engage diverse expertise – including clinical, statistical, computational/data science, and regulatory – across AI development and use. This goes beyond collaboration to formal governance structures: independent challenge mechanisms, clear decision rights, and documented accountability for AI decisions to identify blind spots and ensure robust outcomes.
6. Data governance & documentation	Data Management, Biostatistics	Implement robust governance ensuring data used in AI is fit-for-purpose – with full traceability (lineage), integrity, and management of bias, privacy, representativeness, completeness, and temporal relevance. Regulators scrutinize these elements closely, as data weaknesses are a leading cause of rejected AI evidence in submissions; comprehensive documentation enables reproducible analyses for dossiers.
7. Model design & development	Data Scientists, ML Engineers	Employ reproducible, validated development pipelines that prioritize explainability, avoid overfitting, and justify model choices (e.g., architecture, complexity) against the clinical question and intended context of use. Ensure full traceability from design decisions to performance metrics to withstand regulatory review.
8. Risk-based performance assessment	Validation/QA Teams	Conduct testing scaled to risk, including across subgroups, sites, and stress scenarios, with performance criteria predefined upfront and aligned to intended context of use. Avoid post-hoc metric selection; ongoing lifecycle monitoring ensures sustained fitness-for-purpose, building regulator confidence for pivotal trials and submissions.
9. Life-cycle management	DevOps, Compliance	Establish ongoing governance for AI models throughout their lifecycle – including monitoring for performance drift, version control, change management, retraining/version updates as needed, and planned decommissioning. This ensures models stay fit-for-purpose, compliant, and aligned with evolving regulatory expectations, avoiding post-approval issues.
10. Clear, essential information	Regulatory, Communications	Provide clear, accessible documentation on AI technologies at a level of detail suited to the audience – regulators, reviewers, and users – for submissions and assessments. Focus on essential elements like context, limitations, and performance to facilitate understanding and efficient FDA/EMA interactions.

Key Takeaways:

These principles guide responsible AI practices across the full drug lifecycle – not a checklist for approval or late-stage only.
Compliance builds credibility but doesn’t guarantee acceptance; focus on fitness-for-purpose.
Action for companies: Embed as a governance playbook. Leadership: launch pilots/training. Teams: prioritize documentation. Result? Faster AI rollout, stronger submissions, lower audit risk